Nearly 500 cat tumor samples from five countries have just revealed what scientists never knew before: feline cancer has been hiding the same genetic secrets as human disease. In what researchers are calling one of the largest genetic studies of cat cancers ever completed, an international team of scientists has mapped the mutations driving tumors in domestic cats—work that could transform how we understand and treat cancer in both animals and people.
This matters because cancer ranks among the leading causes of illness and death in cats, yet until now, veterinarians and researchers have operated almost entirely in the dark about what genetic changes spark these tumors. "Despite domestic cats being common pets, there was very little known about the genetics of cancer in these animals," said Dr. Geoffrey Wood, a professor of pathobiology at the University of Guelph and co-senior author of the study published in Science.
The researchers discovered something striking: feline cancers carry many of the same cancer-driving genes found in human and dog tumors. But the most significant finding emerged in mammary cancers. The gene FBXW7 was altered in more than half of the feline mammary tumors studied—and here's where the parallel to human health becomes striking. In human breast cancer, mutations in FBXW7 are associated with poorer outcomes, a pattern that matches almost exactly what scientists observed in cats. The team also identified genetic similarities between feline and human cancers affecting the blood, bones, lungs, skin, gastrointestinal tract, and central nervous system.
Because cats share their homes and environments with their owners, researchers believe some of these cancer risks could stem from common environmental exposures—a clue that may help unlock prevention strategies for both species. As Dr. Wood noted, "This study can help us understand more about why cancer develops in cats and humans, how the world around us influences cancer risk, and possibly find new ways to prevent and treat it."
Perhaps most promising, certain chemotherapy drugs appeared to work better in cat mammary tumors carrying the mutated FBXW7 gene, though the findings were observed only in tissue samples so far. Dr. Sven Rottenberg, co-senior author at the University of Bern, emphasized the scale of what became possible: "Having access to such a large set of donated tissues allowed us to assess drug responses across tumor types, in a way that hasn't been possible at this scale before."
This research exemplifies what scientists call the "One Medicine" approach—a collaborative strategy that encourages knowledge-sharing between veterinary and medical researchers to improve health outcomes across species. The international project brought together researchers from the Wellcome Sanger Institute, the Ontario Veterinary College at the University of Guelph, the University of Bern, and additional institutions, analyzing DNA from tissue samples veterinarians had previously collected for diagnostic purposes.
The implications ripple in multiple directions. Treatments already used in humans could eventually be tested in cats, while information from cancer trials involving domestic cats could guide future human clinical research. Dr. Louise Van Der Weyden, senior author at the Wellcome Sanger Institute, framed the work as a turning point: "We can now begin to take the next steps towards precision feline oncology, to catch up with the diagnostic and therapeutic options available for dogs with cancer, and ultimately one day, humans." For cat owners and cancer researchers alike, this convergence of veterinary and human science offers a rare window into how understanding one species can heal another.